Health and Fitness Health and Fitness
Thu, December 8, 2011
[ Thu, Dec 08th 2011 ] - Market Wire
Bionovo Announces the Publication of its Tissue S .. en Receptor Modulators for Postmenopausal Obesity
[ Thu, Dec 08th 2011 ] - Market Wire
SEQUEL Trial Results for Qnexa Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
[ Thu, Dec 08th 2011 ] - Market Wire
ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress
[ Thu, Dec 08th 2011 ] - Market Wire
The New England Journal of Medicine Publishes Stu .. us Vaccine Demonstrates Protection Against Illnes
[ Thu, Dec 08th 2011 ] - Market Wire
Coronado Biosciences Announces Phase 1 Results of .. e Presented at the American Society of Hematology
[ Thu, Dec 08th 2011 ] - Market Wire
Shire Reports Positive Phase II Results for Inves .. nse (lisdexamfetamine dimesylate) Capsules, (CII)
[ Thu, Dec 08th 2011 ] - Market Wire
Neurologist Survey Confirms Need for Improved Adm .. ation of Parkinson's Disease Acute Rescue Therapy
[ Thu, Dec 08th 2011 ] - Market Wire
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
[ Thu, Dec 08th 2011 ] - Market Wire
Most Couples Prefer Spontaneity in the Bedroom
[ Thu, Dec 08th 2011 ] - Market Wire
Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline
[ Thu, Dec 08th 2011 ] - Market Wire
Auxilium Pharmaceuticals, Inc. Appoints Adrian Adams Chief Executive Officer and President
[ Thu, Dec 08th 2011 ] - Market Wire
Kraig Biocraft Laboratories Announces Filing of I .. on for Spider-Silk and Transgenic Silkworm Techno
[ Thu, Dec 08th 2011 ] - Market Wire
Cord Blood America CEO Matthew Schissler Intervie .. nancial Performance, Stock Price, 2012 Strategies
Wed, December 7, 2011
[ Wed, Dec 07th 2011 ] - Market Wire
Cubist Pharmaceuticals Announces Results of Initi .. ing Shares of Adolor Corporation and Commencement
[ Wed, Dec 07th 2011 ] - Market Wire
Allon Shareholders Approve Balance of October Prospectus Financing
[ Wed, Dec 07th 2011 ] - Market Wire
Watson Launches Generic LoSEASONIQUE(R)
[ Wed, Dec 07th 2011 ] - Market Wire
Hospira Board Announces Retirement of Executive C .. opher B. Begley;; Names John C. Staley Cha
[ Wed, Dec 07th 2011 ] - Market Wire
Lakeland Industries, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results
[ Wed, Dec 07th 2011 ] - Market Wire
The Briscoe Law Firm and Powers Taylor, LLP Annou .. Breaches of Fiduciary Duty by the Officers and D
[ Wed, Dec 07th 2011 ] - Market Wire
Aeolus to Present at the 22nd Annual Oppenheimer Healthcare Conference
[ Wed, Dec 07th 2011 ] - Market Wire
International Drug &;; Explosives Detec .. Signs Marketing Agreement With Company From China
[ Wed, Dec 07th 2011 ] - Market Wire
VistaGen Therapeutics and Synterys Sign Strategic .. Chemistry Collaboration Agreement for Drug Rescue
[ Wed, Dec 07th 2011 ] - Market Wire
Leading Investigator to Present Clinical Data on .. ternational Diabetes Federation Meetings in Dubai
[ Wed, Dec 07th 2011 ] - Market Wire
Benefits of VentriPoint's VMS(TM) System to Be Presented at Prestigious Heart Conference
[ Wed, Dec 07th 2011 ] - Market Wire
Theratechnologies to Discontinue COPD Clinical Program and Accelerate Path to Profitability
[ Wed, Dec 07th 2011 ] - Market Wire
MuGard Advocate Interviewed on ABC Tampa News at Noon
[ Wed, Dec 07th 2011 ] - Market Wire
Novelos Therapeutics Closes $6 Million Public Offering
[ Wed, Dec 07th 2011 ] - Market Wire
Aoxing Pharmaceutical Company Announces $3.2 Million Financing
[ Wed, Dec 07th 2011 ] - Market Wire
Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
[ Wed, Dec 07th 2011 ] - Market Wire
InterMune to Present at Oppenheimer & Co. 22nd Annual Healthcare Conference on Dec. 14

InterMune to Present at Oppenheimer & Co. 22nd Annual Healthcare Conference on Dec. 14


Published on 2011-12-07 05:15:59 - Market Wire
  Print publication without navigation


InterMune to Present at Oppenheimer & Co. 22nd Annual Healthcare Conference on... -- BRISBANE, Calif., Dec. 7, 2011 /PRNewswire/ --

InterMune to Present at Oppenheimer & Co. 22nd Annual Healthcare Conference on Dec. 14

[ ]

 

BRISBANE, Calif., Dec. 7, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: [ ITMN ]) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Oppenheimer & Co. 22nd Annual Healthcare Conference in New York City on Wednesday, December 14, 2011, at 3:55 p.m. EST. 

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at [ www.intermune.com ]. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit [ www.intermune.com ].

SOURCE InterMune, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.intermune.com ]

Contributing Sources